Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Halozyme Therapeutics, Inc. (HALO) had Receiveable Turnover of 3.29 for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$1.02B |
|
$444.09M |
|
$159.42M |
|
$855.91M |
|
$463.85M |
|
$551.48M |
|
$5.66M |
|
$557.13M |
|
$557.13M |
|
$444.09M |
|
$444.09M |
|
$444.09M |
|
$444.09M |
|
$551.48M |
|
$629.22M |
|
126.83M |
|
129.42M |
|
$3.50 |
|
$3.43 |
|
| Balance Sheet Financials | |
$1.09B |
|
$75.03M |
|
$978.14M |
|
$2.06B |
|
$139.10M |
|
$1.51B |
|
$1.56B |
|
$1.70B |
|
$363.82M |
|
$-454.83M |
|
$363.82M |
|
123.14M |
|
| Cash Flow Statement Financials | |
$479.06M |
|
$-262.72M |
|
$-218.86M |
|
$118.37M |
|
$115.85M |
|
$-2.52M |
|
$43.38M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.80 |
|
-- |
|
-- |
|
0.81 |
|
4.14 |
|
84.30% |
|
54.32% |
|
54.32% |
|
61.97% |
|
54.87% |
|
43.74% |
|
$468.37M |
|
-- |
|
-- |
|
-- |
|
0.49 |
|
1.12 |
|
|
Receiveable Turnover |
3.29 |
110.89 |
|
122.06% |
|
-97.64% |
|
21.52% |
|
23.75% |
|
$2.95 |
|
$3.62 |
|
$3.70 |
|